Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

by Business Wire • 2026/08/03 • 0 Comments

BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #biosimilar--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg, Used to Treat Various Types of Ophthalmology Conditions

← Don't Let "The Blur" Stand in the Way of Children's Learning

Refractive surgery embraces era of corneal preservation →

Post navigation